# The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Overall survival following hematopoietic cell trans-plantation (HCT) has improved over the past two decades through better patient selection and advances in HLA typing, supportive care, and infection prophylaxis. Nonetheless, mor-tality rates are still unsatisfactory and transplant-related mor-tality remains a major cause of death after unrelated allogeneic HCT. Since there are no known pre-HCT, non-HLA biologic predictors of survival following transplant, for over a decade, scientists have been investigating the role of non-HLA germline genetic variation in survival and treatment-related mortality after HCT. Variation in single nucleotide polymor-...
Alkylating agents with or without ionizing radiation are frequently used in pretransplant conditioni...
Allogeneic hematopoietic stem cell transplantation (SCT) remains the only available curative therapy...
The advantage of using a Human Leukocyte Antigen (HLA)-mismatched related donor is that almost every...
AbstractDespite optimal supportive care and high-resolution HLA matching, complications such as GVHD...
Copyright © 2007 American Society for Blood and Marrow Transplantation Published by Elsevier Inc.Des...
Allogeneic haemopoietic stem cell transplantation is curative for many patients with haematologic di...
Contains fulltext : 88164.pdf (publisher's version ) (Open Access)BACKGROUND: Non-...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Graft-versus-host Disease (GVHD) is the main cause of morbidity and mortality after allogeneic hemat...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Alkylating agents with or without ionizing radiation are frequently used in pretransplant conditioni...
Allogeneic hematopoietic stem cell transplantation (SCT) remains the only available curative therapy...
The advantage of using a Human Leukocyte Antigen (HLA)-mismatched related donor is that almost every...
AbstractDespite optimal supportive care and high-resolution HLA matching, complications such as GVHD...
Copyright © 2007 American Society for Blood and Marrow Transplantation Published by Elsevier Inc.Des...
Allogeneic haemopoietic stem cell transplantation is curative for many patients with haematologic di...
Contains fulltext : 88164.pdf (publisher's version ) (Open Access)BACKGROUND: Non-...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Graft-versus-host Disease (GVHD) is the main cause of morbidity and mortality after allogeneic hemat...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
IntroductionData on genomic susceptibility for adverse outcomes after hematopoietic stem cell transp...
Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative optio...
Alkylating agents with or without ionizing radiation are frequently used in pretransplant conditioni...
Allogeneic hematopoietic stem cell transplantation (SCT) remains the only available curative therapy...
The advantage of using a Human Leukocyte Antigen (HLA)-mismatched related donor is that almost every...